Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
Fibroblast Activity Assessed by NordicPRO-C3™ is Prognostic for Fibrosis Progression in MASH
May 7, 2025
Fibroblast activity assessed by PRO-C3 is prognostic for fibrosis progression in MASH patients treated with insulin sensitizer MSDC-0602K during a phase IIb clinical trial
Introduction
Liver fibrosis is a dynamic process driven by hepatic stellate and other mesenchymal cells forming ECM and disrupting normal organ architecture, while releasing ECM fragments into the bloodstream. These fragments are surrogates of ECM formation that can be leveraged as fibrosis biomarkers. In this study, we measured biomarkers of collagen type III and type VI (nordicPRO-C3™ and nordicPRO-C6™) during EMMINENCE, a phase IIb clinical trial testing MSDC-0602K, an insulin sensitizer in MASH patients.
Poster
Conclusion
Lower fibroblast activity (nordicPRO-C3™) at baseline was associated with achieving primary endpoint as well as fibrosis regression, while higher baseline nordicPRO-C3™ was associated with fibrosis progression. MSDC-0602K significantly reduced nordicPRO-C3™ and nordicPRO-C6™, suggesting an anti-fibrotic and pro-metabolic effect. NordicPRO-C3™ can identify MASH patients who are likely to respond to treatment and prognosticate their evolution.
